Axxcess Wealth Management LLC Has $1.81 Million Stock Position in AstraZeneca PLC $AZN

Axxcess Wealth Management LLC boosted its stake in shares of AstraZeneca PLC (NASDAQ:AZN) by 17.7% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 23,530 shares of the company’s stock after purchasing an additional 3,541 shares during the period. Axxcess Wealth Management LLC’s holdings in AstraZeneca were worth $1,805,000 as of its most recent filing with the SEC.

Several other institutional investors have also recently made changes to their positions in the stock. May Hill Capital LLC grew its position in shares of AstraZeneca by 6.9% in the 3rd quarter. May Hill Capital LLC now owns 9,827 shares of the company’s stock valued at $754,000 after acquiring an additional 634 shares during the period. Vista Investment Management raised its holdings in shares of AstraZeneca by 5.7% in the 3rd quarter. Vista Investment Management now owns 21,155 shares of the company’s stock valued at $1,623,000 after purchasing an additional 1,149 shares during the period. Crestwood Advisors Group LLC lifted its stake in AstraZeneca by 10.5% in the 3rd quarter. Crestwood Advisors Group LLC now owns 525,251 shares of the company’s stock valued at $40,297,000 after purchasing an additional 50,068 shares during the last quarter. NEOS Investment Management LLC grew its holdings in AstraZeneca by 79.3% during the third quarter. NEOS Investment Management LLC now owns 185,132 shares of the company’s stock worth $14,203,000 after purchasing an additional 81,900 shares during the period. Finally, Holistic Financial Partners raised its stake in AstraZeneca by 9.0% in the third quarter. Holistic Financial Partners now owns 4,543 shares of the company’s stock valued at $349,000 after buying an additional 376 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

Analysts Set New Price Targets

A number of research analysts recently weighed in on AZN shares. Weiss Ratings reissued a “buy (b)” rating on shares of AstraZeneca in a report on Wednesday, January 21st. TD Cowen reaffirmed a “buy” rating on shares of AstraZeneca in a research report on Tuesday, December 9th. Deutsche Bank Aktiengesellschaft reissued a “sell” rating on shares of AstraZeneca in a research report on Friday, February 6th. Barclays reissued an “overweight” rating on shares of AstraZeneca in a report on Tuesday, January 6th. Finally, Citigroup began coverage on AstraZeneca in a research report on Tuesday, January 27th. They set a “buy” rating on the stock. Nine equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to MarketBeat.com, AstraZeneca currently has an average rating of “Moderate Buy” and a consensus price target of $95.75.

AstraZeneca Stock Performance

AZN stock opened at $208.76 on Friday. The firm has a market cap of $323.77 billion, a PE ratio of 69.36, a price-to-earnings-growth ratio of 1.59 and a beta of 0.34. AstraZeneca PLC has a 1-year low of $122.48 and a 1-year high of $212.71. The stock has a 50-day moving average price of $122.11 and a 200-day moving average price of $96.53. The company has a current ratio of 0.88, a quick ratio of 0.69 and a debt-to-equity ratio of 0.54.

AstraZeneca Announces Dividend

The business also recently disclosed a dividend, which will be paid on Monday, March 23rd. Stockholders of record on Friday, February 20th will be paid a $1.595 dividend. The ex-dividend date of this dividend is Friday, February 20th. This represents a dividend yield of 153.0%. AstraZeneca’s dividend payout ratio is 74.83%.

AstraZeneca Profile

AstraZeneca is a global, science-led biopharmaceutical company headquartered in Cambridge, England. Formed through the 1999 merger of Sweden’s Astra AB and the UK’s Zeneca Group, the company researches, develops, manufactures and commercializes prescription medicines across a range of therapeutic areas. AstraZeneca’s operations span research and development, large-scale manufacturing, and commercial distribution, with a presence in developed and emerging markets worldwide.

The company focuses on several core therapy areas including oncology, cardiovascular, renal and metabolism (CVRM), respiratory and immunology, and rare diseases.